美国皮肤科学会联合基金会发布粉刺性痤疮护理指南
Recommendations developed for management of hidradenitis suppurativa
美国皮肤科学会与 Hidradenitis Suppurativa 基金会联合发布护理指南,包含37项证据建议,涵盖生物制剂(如阿达木单抗)、局部治疗(克林霉素、雷索替尼)及激素疗法(螺内酯)等。该指南为患者、医生和支付方提供统一标准。
原文基于系统综述提出37条管理建议,为患者、医生和支付方提供统一标准,临床实践可参考此更新诊疗流程。
Evidence-based recommendations are presented for the management of hidradenitis suppurativa (HS) in guidelines of care issued by the American Academy of Dermatology and the Hidradenitis Suppurativa Foundation and published online Oct. 20 in the Journal of the American Academy of Dermatology.
Haley B. Naik, M.D., from the University of California in San Francisco, and colleagues conducted a systematic review to provide evidence-based recommendations for the management of HS.
The authors presented 37 evidence-based recommendations. Adalimumab, bimekizumab, infliximab, secukinumab and routine pain assessment were strongly recommended. Conditional recommendations included use of topical therapies (clindamycin, resorcinol and ruxolitinib), as well as systemic antibiotics (oral doxycycline, tetracycline, clindamycin with rifampin and intravenous ertapenem). In addition, there were conditional recommendations for hormone therapy with spironolactone, short-term systemic corticosteroids and upadacitinib. Specific procedural interventions, tobacco cessation, supportive pain management, and zinc supplementation and vitamin D repletion were also conditionally recommended.
"These guidelines establish an evidence-based standard of care for HS, giving patients, dermatologists and payers a shared roadmap for what high-quality HS care looks like," Naik said in a statement. "Every person living with HS deserves care that meets this standard."
Publication details
Haley B. Naik et al., Joint American Academy of Dermatology-Hidradenitis Suppurativa Foundation guidelines of care for the management of hidradenitis suppurativa, Journal of the American Academy of Dermatology (2026). DOI: 10.1016/j.jaad.2026.08.125
Journal information: Journal of the American Academy of Dermatology
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
© 2026 HealthDay. All rights reserved.
Citation: Recommendations developed for management of hidradenitis suppurativa (2026, October 28) retrieved 28 October 2026 from https://medicalxpress.com/news/2026-10-hidradenitis-suppurativa.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com